Cargando…
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial
BACKGROUND: This analysis was initiated to define the predictive value of the area under the curve of high-dose methotrexate (AUC(HD-MTX)) in patients with primary central nervous system lymphoma (PCNSL). PATIENTS AND METHODS: We included 55 patients with PCNSL and available pharmacokinetic (PK) dat...
Autores principales: | Joerger, M, Huitema, A D R, Krähenbühl, S, Schellens, J H M, Cerny, T, Reni, M, Zucca, E, Cavalli, F, Ferreri, A J M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837574/ https://www.ncbi.nlm.nih.gov/pubmed/20125159 http://dx.doi.org/10.1038/sj.bjc.6605559 |
Ejemplares similares
-
Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas
por: Ferreri, A J M, et al.
Publicado: (2004) -
IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma
por: Pirosa, Maria Cristina, et al.
Publicado: (2022) -
Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017) -
Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
por: Crombag, Marie-Rose B.S., et al.
Publicado: (2016) -
S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT01599559)
por: Martelli, Maurizio, et al.
Publicado: (2023)